Cotinine-conjugated aptamer/anti-cotinine antibody complexes as a novel affinity unit for use in biological assays.

Abstract

Aptamers are synthetic, relatively short (e.g., 20-80 bases) RNA or ssDNA oligonucleotides that can bind targets with high affinity and specificity, similar to antibodies, because they can fold into unique, three-dimensional shapes. For use in various assays and experiments, aptamers have been conjugated with biotin or digoxigenin to form complexes with avidin or anti-digoxigenin antibodies, respectively. In this study, we developed a method to label the 5' ends of aptamers with cotinine, which allows formation of a stable complex with anti-cotinine antibodies for the purpose of providing another affinity unit for the application in biological assays using aptamers. To demonstrate the functionality of this affinity unit in biological assays, we utilized two well-known aptamers: AS1411, which binds nucleolin, and pegaptanib, which binds vascular endothelial growth factor. Cotinine-conjugated AS1411/ anti-cotinine antibody complexes were successfully applied to immunoblot, immunoprecipitation, and flow cytometric analyses, and cotinine-conjugated pegaptanib/ anti-cotinine antibody complexes were used successfully in enzyme immunoassays. Our results show that cotinine-conjugated aptamer/anti-cotinine antibody complexes are an effective alternative and complementary technique for aptamer use in multiple assays and experiments.

Full text

Page 1

1

Cotinine-conjugated Aptamer/Anti-cotinine Antibody Complexes as a Novel
1
Affinity Unit for Use in Biological Assays
2

3
Sunyoung Park1,2, Dobin Hwang1,2, and Junho Chung1,2,3
4

5
1Department of Biochemistry and Molecular Biology
6
Seoul National University College of Medicine
7
Seoul 110-799, Korea
8
2Cancer Research Institute
9
Seoul National University
10
Seoul 110-799, Korea
11
3Corresponding author: Tel, 82-2-3668-7441; Fax, 82-2-747-5769; E-mail,
12
jjhchung@snu.ac.kr
13

14
Running title: Novel affinity unit for aptamers
15

16

17

18

19

20

21

22

23

24

25

26

27

Page 2

2

Abstract
28

29
Aptamers are synthetic, relatively short (e.g., 20-80 bases) RNA or ssDNA
30
oligonucleotides that can bind targets with high affinity and specificity, similar to
31
antibodies, because they can fold into unique, three-dimensional shapes. For use in
32
various assays and experiments, aptamers have been conjugated with biotin or
33
digoxigenin to form complexes with avidin or anti-digoxigenin antibodies, respectively.
34
In this study, we developed a method to label the 5' ends of aptamers with cotinine,
35
which allows formation of a stable complex with anti-cotinine antibodies for the purpose
36
of providing another affinity unit for the application in biological assays using aptamers.
37
To demonstrate the functionality of this affinity unit in biological assays, we utilized two
38
well-known aptamers: AS1411, which binds nucleolin, and pegaptanib, which binds
39
vascular endothelial growth factor. Cotinine-conjugated AS1411/anti-cotinine antibody
40
complexes were successfully applied to immunoblot, immunoprecipitation, and flow
41
cytometric analyses, and cotinine-conjugated pegaptanib/anti-cotinine antibody
42
complexes were used successfully in enzyme immunoassays. Our results show that
43
cotinine-conjugated aptamer/anti-cotinine antibody complexes are an effective
44
alternative and complementary technique for aptamer use in multiple assays and
45
experiments.
46

47
Keywords: aptamer; cotinine; flow cytometry; immunoblot; immunoprecipitation;
48
enzyme-linked immunoassay
49

50

51

52

53

54

Page 3

3

Introduction
55

56
Aptamers are synthetic, relatively short (e.g., 20-80 bases) RNA or ssDNA
57
oligonucleotides that can fold into unique, three-dimensional shapes. Aptamers can
58
bind targets with high affinity and specificity and were first described as affinity
59
molecules for protein binding in 1990 (Ellington and Szostak, 1990; Tuerk and Gold,
60
1990). Following the development of the SELEX (systematic evolution of ligands by
61
exponential enrichment) method, the isolation of aptamers specific to various targets
62
has become more efficient and easier to perform (Oguro et al., 2003; Miyakawa et al.,
63
2006; Ohuchi et al., 2006). Aptamers can form stable and specific complexes with a
64
wide variety of targets, including low molecular compounds such as amino acids
65
(Harada and Frankel, 1995; Yang et al., 1996) and complex protein targets such as cell
66
membrane proteins (Ulrich et al., 1998; Homann and Goringer, 1999; Blank et al.,
67
2001; Ulrich et al., 2002; Guo et al., 2006). Therefore, aptamers have been used in a
68
variety of methods in which antibodies are commonly used, such as in enzyme
69
immunoassays, immunoprecipitation analyses, flow cytometric analyses (Ireson and
70
Kelland, 2006; Ferreira et al., 2008; Sakai et al., 2008), protein microarrays (Chen et al.,
71
2008), magnetic-separation assays (Gao et al., 2007), lateral flow assays (Liu et al.,
72
2007; Shaikh et al., 2007), and biosensor experiments (Backmann et al., 2005; Borisov
73
and Wolfbeis, 2008). For use in such applications, aptamers can be either conjugated
74
to beads or surfaces, or labeled with enzymes or fluorescent dyes. However, because
75
the cross-linking conditions to one enzyme, dye, or sensor cannot be applied to other
76
targets, the determination of specific conditions for aptamer cross-linking to multiple
77
enzymes, dyes, or sensors is a time-consuming process. Therefore, labeling of
78
aptamers with biotin to produce complexes with avidin, streptavidin, or neutravidin in
79
various cross-linked forms has been commonly employed when an aptamer is to be
80
applied to multiple assays (Murphy et al., 2003; Baldrich et al., 2005; Li et al., 2009;
81

Page 4

4

Tanaka et al., 2009). Additionally, aptamers have been labeled with digoxigenin to
82
produce complexes with anti-digoxigenin antibodies (Ramos et al., 2007; Ramos et al.,
83
2010).
84
In this report, we introduce cotinine-conjugated aptamer/anti-cotinine antibody
85
complexes as an alternative and complementary platform for the use of aptamers in
86
biological assays. We utilized two well-known aptamers: AS1411 that binds nucleolin
87
(Bates et al., 1999; Dapic et al., 2002; Dapic et al., 2003) and pegaptanib that binds
88
vascular endothelial growth factor (VEGF) (Ruckman et al., 1998; Ng and Adamis,
89
2006). Cotinine-conjugated AS1411/anti-cotinine antibody complexes were successfully
90
applied to immunoblot, immunoprecipitation, and flow cytometric analyses, and
91
cotinine-conjugated pegaptanib/anti-cotinine antibody complexes were successfully
92
used in enzyme immunoassays.
93

94
Results
95

96
Binding of AS1411-cotinine/anti-cotinine antibody complexes to cell-surface
97
nucleolin
98

99
To assess whether AS1411-cotinine/anti-cotinine antibody complexes (Figures 1, 2)
100
bind to nucleolin on cell surfaces, Raji cells were incubated with AS1411-cotinine/anti-
101
cotinine antibody complexes and FITC-labeled anti-human IgG antibodies. With the
102
concentration of anti-cotinine antibody fixed at 100 nM, cotinine-conjugated AS1411 at
103
concentrations of 1, 10, and 100 nM bound to the cell surface in a dose-dependent
104
manner (Figure 3A). As an IgG molecule, an anti-cotinine antibody contains two
105
paratopes and can form a complex with two molecules of AS1411-cotinine. When either
106
CRO26 (Figure 2) or an isotype control for anti-cotinine antibody was used instead of
107
AS1411 or anti-cotinine antibody, respectively, binding of the complex was not
108

Page 5

5

observed. CRO26, the negative control of AS1411, is an oligonucleotide in which each
109
dG of AS1411 is replaced by dC, which blocks both the formation of a stable
110
quadruplex structure and nucleolin binding (Soundararajan et al., 2009).
111
We then performed flow cytometric analysis with AS1411-cotinine/anti-cotinine antibody
112
complexes using three additional cell lines that were reported previously to possess
113
different cell surface expression levels of nucleolin (Semenkovich et al., 1990;
114
Hanakahi et al., 1997; Masumi et al., 2006). With 50 nM AS1411-cotinine and 100 nM
115
anti-cotinine antibody, the complex showed stronger binding to HepG2 and U87MG
116
cells and weaker binding to NIH3T3 cells compared to Raji cells (Figure 3B).
117

118
AS1411-cotinine/anti-cotinine antibody complex recognition of denatured
119
nucleolin
120

121
To determine whether AS1411-cotinine/anti-cotinine antibody complexes recognize the
122
denatured form of nucleolin, we performed immunoblot analyses (Figure 4A). Raji cell
123
lysate (50 μg) was subjected to SDS-PAGE, proteins were transferred to a
124
nitrocellulose membrane, and the membrane was incubated sequentially with AS1411-
125
cotinine/anti-cotinine antibody complexes, HRP-conjugated anti-human IgG antibody,
126
and chemiluminescent substrate solution, with intermittent washing with TBST.
127
AS1411-cotinine/anti-cotinine antibody complexes reacted not only to full-length
128
nucleolin (105 kDa) but also to lower molecular mass forms of nucleolin (<40 kDa) that
129
have been previously reported to be generated by nucleolin autolytic activity (Figure
130
4A) (Chen et al., 1991; Fang and Yeh, 1993). In contrast, mouse anti-nucleolin
131
antibody reacted only to full-length nucleolin. When either CRO26 or palivizumab was
132
used instead of AS1411 or anti-cotinine antibody, respectively, no bands were
133
visualized.
134

135

Page 6

6

AS1411-cotinine/anti-cotinine antibody complex immunoprecipitation of
136
nucleolin
137

138
Raji cell lysate was incubated with AS1411-cotinine/anti-cotinine antibody complexes
139
overnight. Complexes were then immunoprecipitated using protein A beads and
140
subjected to SDS-PAGE. After the proteins were transferred to a nitrocellulose
141
membrane, immunoblot analysis was performed using anti-nucleolin antibody. A protein
142
band with a molecular weight of 105 kDa was visualized, confirming that AS1411-
143
cotinine/anti-cotinine antibody complexes successfully immunoprecipitated nucleolin
144
from Raji cell lysates (Figure 4B). However, when either CRO26 or palivizumab was
145
used instead of AS1411 or anti-cotinine antibody, respectively, no bands were
146
visualized.
147

148
Specific binding of pegaptanib-cotinine/anti-cotinine antibody complexes to
149
VEGF165
150

151
To verify whether pegaptanib-cotinine/anti-cotinine antibody complexes (Figure 1, 2)
152
can bind to immobilized VEGF165 on a microtiter plate, we performed an enzyme
153
immunoassay using a VEGF165-coated microtiter plate, cotinine-conjugated
154
pegaptanib/anti-cotinine antibody complexes, and HRP-conjugated anti-human IgG
155
antibody. Cotinine-conjugated pegaptanib/anti-cotinine antibody complexes bound to
156
VEGF165 on the plate in a dose-dependent manner from 10-1 to 103 pM (Figure 5). In a
157
parallel experiment, bevacizumab showed dose-dependent binding to VEGF165.
158

159
Discussion
160

161
For application of aptamers in multiple assays and experiments, biotin labeling has
162

Page 7

7

been the most commonly adopted option to avoid the need to develop optimal aptamer
163
cross-linking conditions for multiple enzymes, dyes, or sensors individually (Murphy et
164
al., 2003; Baldrich et al., 2005; Li et al., 2009; Tanaka et al., 2009). Because biotin is
165
stable and small (molecular weight of 244.31 kDa), it rarely interferes with the function
166
of labeled molecules. The avidin-biotin detection system allows an aptamer to be easily
167
captured, recovered, immobilized, or detected with a limited number of secondary
168
detection reagents generated by modifying avidin, streptavidin, or neutravidin. A major
169
limitation of this system is that biotin, as vitamin B7, is present in small amounts in all
170
living cells and participates in many biological processes including cell growth and the
171
citric acid cycle (Bender, 1999). Biotin is especially abundant in tissues such as brain,
172
liver, and blood, and endogenous biotin can cause considerable background noise in
173
assays based on biotin binding (Ramos-Vara, 2005).
174
Digoxigenin also has been used to label aptamers for use in biological assays (Ramos
175
et al., 2007; Ramos et al., 2010). It is a steroid with a low molecular weight of 390.51
176
Da that is found exclusively in the flowers and leaves of plants such as Digitalis
177
purpuea, Digitalis orientalis, and Digitalis lanata. Additionally, digoxigenin is a hapten
178
with high immunogenicity (Holtke et al., 1995). It also has served as a standard
179
immunohistochemical marker for in situ hybridization (Hauptmann and Gerster, 1994).
180
For labeling of atpamers, digoxigenin can be conjugated to a nucleotide triphosphate,
181
and the labeled nucleotide triphosphate is then used in aptamer synthesis. The
182
resulting digoxigenin-labeled aptamer can form a complex with anti-digoxigenin
183
antibody for applications in assays and experiments.
184
In this study, we aimed to develop an additional hapten-labeled aptamer and anti-
185
hapten antibody system that can be applied to develop multiplex aptamer assays.
186
Based on several of its characteristics, we selected and tested cotinine as a candidate
187
hapten for labeling aptamers. In a previous study, we showed that anti-cotinine
188
antibody can be generated by immunization of animals with cotinine-conjugated carrier
189

Page 8

8

proteins (Park et al., 2010). Cotinine is the major metabolite of nicotine found in
190
tobacco smoke, and cotinine-labeled horseradish peroxidase is sufficiently stable to
191
give consistent results in enzyme immunoassays (Park et al., 2010). Because cotinine
192
has a low molecular weight of 176.22 Da, we hypothesized that it would not alter the
193
function of an aptamer upon conjugation. Both cotinine-conjugated AS1411 and
194
cotinine-conjugated pegaptanib retained their reactivity to their original targets in this
195
study. As both cotinine and its binding molecules are not present physiologically in
196
animal and human tissues, minimal background signal was expected. As shown in
197
Figure 4, the AS1411-cotinine/anti-cotinine antibody complex recognized denatured
198
nucleolin with minimal background.
199
Taken together, our results demonstrate that cotinine-conjugated aptamer/anti-cotinine
200
antibody complexes can be used in applications such as flow cytometric, immunoblot,
201
immunoprecipitation, and enzyme immunoassay analyses, providing a viable
202
alternative for employing cotinine-labeled aptamers in multiple assays and experiments,
203
alone or in combination with biotin- and/or digoxigenin-labeled aptamers. Additionally,
204
the stability of the complex and successful retention of aptamer reactivity make this
205
system suitable for potential in vivo application.
206

207
Methods
208

209
Preparation of aptamer-cotinine conjugates
210

211
The aptamers used in this study were AS1411, 5′-
212
d(GGTGGTGGTGGTTGTGGTGGTGGTGG)-3′, an inactive control aptamer (CRO26),
213
5′-d(CCTCCTCCTCCTTCTCCTCCTCCTCC)-3′, and pegaptanib, 5′-
214
pCfpGmpGmpArpArpUfpCfpAmpGmpUfpGmpAmpAm
215

Page 9

9

pUfpGmpCfpUfpUfpAmpUfpAmpCfpAmpUfpCfpCfpGm3′-p-dT). These aptamers were
216
synthesized with an amino C6 linker at the 5′-terminus by ST Pharm Co. (Seoul, South
217
Korea). All the aptamers were conjugated to cotinine using the active ester method as
218
described previously (Park et al., 2010), purified to homogeneity (i.e., >95% purity) in
219
reversed-phase high-pressure liquid chromatography with an Xbridge Prep C18
220
column (5 µm, 10 × 150 mm, Waters Corp., Milford, MA). The quality of conjugated
221
aptamers was analyzed with an ion-trap mass spectrometer through electrospray
222
ionization (ESI-IT/MS) by Postech Aptamer Initiative (Pohang, South Korea). AS1411-
223
cotinine and CRO26-cotinine conjugates were dissolved in water; pegaptanib-cotinine
224
conjugates were dissolved in diethyl pyrocarbonate-treated water. All aptamer-cotinine
225
conjugates were aliquoted and stored at -20°C. Before use, all the aptamers were
226
denatured at 95°C for 5 min and slowly cooled to 25°C over 30 min.
227

228
Antibodies
229

230
Mouse anti-nucleolin antibody was purchased from Santa Cruz Biotechnology (Santa
231
Cruz, CA). Palivizumab (Synagis, Abbot Laboratories, Kent, UK) and bevacizumab
232
(Avastin, Genentech Inc, South San Francisco, CA) were used as control antibodies.
233
Fluorescein isothiocyanate (FITC)- and horseradish peroxidase (HRP)-conjugated anti-
234
human Fc antibodies were purchased from Thermo Fisher Scientific (Rockford, IL).
235
The recombinant rabbit/human chimeric anti-cotinine antibody used in this study was
236
originally generated through a form of scFv for use in an enzyme immunoassay for
237
detecting cotinine in the biological fluids of smokers (Park et al., 2010). For the
238
construction of an expression vector for anti-cotinine IgG, the genes encoding the
239
variable regions of the heavy chain (VH) and light chain (VL) were amplified from an
240
anti-cotinine scFv-Fc expression vector using 5'-
241

Page 10

10

ATCCTGTTCCTGGTGGCCACCGCCACCGGCCAGTCGGTGAAGGAGTCC-3' and 5'-
242
ATCCTGTTCCTGGTGGCCACCGCCACCGGCGAGCTCGATCTGACCCAG-3' as the
243
5' primers and 5'-TGAAGAGATGGTGACCAGGGTGCC-3' and 5'-
244
TAGGATCTCCAGCTCGGTCCCTCC-3' as the 3' primers, respectively (Park et al.,
245
2010). Human VH constant region (CH1–CH3) and human VL constant region (Cκ)
246
were amplified from a human bone marrow cDNA library (Clontech Laboratories, Inc.,
247
Palo Alto, CA) using 5'-GTCACCATCTCTTCAGCCTCCACCAAGGGC-3' and 5'-
248
GAGCTCGGATCCCTTGCCGGCCGT-3' as the 5' primers and 5'-
249
GAGCTGGAGATCCTACGGACCGTGGCCGCC-3'’ and 5'-
250
GCAAGCTCTAGACTAGCACTCGCC-3' as the 3' primers, which contain an annealing
251
site for both VH and VL. Overlap extension polymerase chain reaction (PCR) was
252
performed using 5'-
253
ACATCGGCTAGCCGCCACCATGGGCTGGTCCTGCATCATCCTGTTCCTG-3' and 5'-
254
ACTTAAGCTTGCGCCACCATGGGCTGGTCCTGCATCATCCTGTTCCTG-3' as the 5'
255
primers and 5'-GAGCTCGGATCCCTTGCCGGCCGT-3' and 5'-
256
GCAAGCTCTAGACTAGCACTCGCC-3' as the 3' primers to generate genes encoding
257
the complete VH and VL fragments, respectively. The complete VH and VL DNAs were
258
digested, respectively, with BamHI and NheI and with HindIII and XbaI (New England
259
Biolabs Inc., Beverly, MA) and inserted into an expression vector designed for
260
mammalian secretion of full-length IgGs. The vector encoding anti-cotinine IgG was
261
used to transfect CHO DG44 cells (Invitrogen, Carlsbad, CA) as described previously
262
(Trill et al., 1995). Overexpressed anti-cotinine IgG was purified by protein A-gel affinity
263
chromatography according to the manufacturer’s instructions (Repligen Corp.,
264
Cambridge, MA).
265

266
Cell culture
267

268

Page 11

11

Adherent CHO DG44 cells were cultivated at 37°C under an atmosphere of 95% air
269
and 5% CO2 in CD DG44 media (GIBCO, Invitrogen) containing 100 U/mL penicillin
270
and 100 g/mL streptomycin, and supplemented with 10 μM hypoxanthine, 1.6 μM
271
thymidine, 8 mM L-glutamine, and 18 mg/L Pluronic F-68 (GIBCO).
272
Raji (human Burkitt’s lymphoma), HepG2 (human hepatocellular carcinoma), U87MG
273
(human glioblastoma), and NIH3T3 (mouse embryonic fibroblast) cells were obtained
274
from American Type Culture Collection. Cells were grown in RPMI 1640 (GIBCO)
275
culture media containing 10% fetal bovine serum (FBS; GIBCO), 100 U/mL penicillin,
276
and 100 g/mL streptomycin at 37°C in 5% CO2.
277

278
Flow cytometric analysis
279

280
Raji, HepG2, U87MG, and NIH3T3 cells (1×105 cells/mL) were resuspended in 100 μL
281
flow cytometric assay buffer [1% FBS and 0.02% sodium azide in phosphate-buffered
282
saline (PBS)] and incubated with the indicated concentrations of AS1411-cotinine and
283
100 nM anti-cotinine antibody at 4°C for 20 min. As a control, CRO26-cotinine and
284
palivizumab were used in place of AS1411-cotinine and anti-cotinine antibody,
285
respectively. After washing twice with flow cytometric assay buffer, cells were incubated
286
with FITC-labeled anti-human IgG (Thermo Fisher Scientific) at 4°C for 15 min and
287
washed again with flow cytometric assay buffer. The cells were fixed with PBS
288
containing 2% paraformaldehyde; fluorescence intensity was measured using
289
FACSCanto™ II (BD Bioscience, Heidelberg, Germany) and analyzed with FlowJo data
290
analysis software (Treestar, Ashland, OR).
291

292
Immunoblot analysis
293

294

Page 12

12

Raji cells were harvested by centrifugation at 168 g for 3 min at 4°C and then washed
295
three times with PBS. The pellet was resuspended in 1 mL lysis buffer (20 mM Tris-Cl,
296
pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.25 mM synthetic dextrose complete medium,
297
1 mM PMSF, 1 μg/mL aprotinin, 1 μg/mL leupeptin, and 1 μg/ml pepstatin A) and
298
sonicated for three rounds, 10 s each at an output setting of 7 (Sonic Dismembrator
299
model 500, Thermo Fisher Scientific). The sonicated samples were cleared by
300
centrifugation for 10 min at 17,000 g, and the amount of protein in the supernatants
301
was measured by Bradford assay (Bio-Rad, Hercules, CA). The lysate (50 µg) was
302
dissolved in 4× SDS loading buffer (50 mM MES, 50 mM Tris-base, 0.1% SDS, 1 mM
303
EDTA, and 50 mM dithiothreitol, pH 7.3) and separated by SDS-polyacrylamide gel
304
electrophoresis (SDS-PAGE) using 4-12% Bis-Tris gel (Invitrogen) followed by transfer
305
onto a nitrocellulose membrane (Whatman, Dassel, Germany) using an XCell
306
SureLock™ Novex Mini-Cell (Invitrogen) at 40 V for 60 min. The membrane was pre-
307
incubated in TBST (10 mM Tris, pH 7.5, 150 mM NaCl, and 0.1% Tween-20)
308
containing 5% non-fat milk (BD Biosciences Diagnostic Systems, Sparks, MD) at room
309
temperature for 30 min and then incubated with 100 nM AS1411-cotinine/50 nM anti-
310
cotinine antibody complexes, 100 nM AS1411-cotinine/50 nM control antibody
311
complexes, 100 nM CRO26-cotinine/50 nM anti-cotinine antibody complexes, or a
312
1:100 dilution of mouse anti-nucleolin antibody (Santa Cruz Biotechnology) at room
313
temperature for 2 h. After the membrane was washed three times with TBST, it was
314
incubated with either HRP-conjugated rabbit anti-human IgG antibody (Thermo Fisher
315
Scientific) or HRP-conjugated anti-mouse IgG antibody (Thermo Fisher Scientific)
316
diluted 1:5,000 in TBST at room temperature for 1 h. The membrane was washed three
317
times with TBST, and protein bands were visualized by the addition of SuperSignal
318
Pico West chemiluminescent substrate (Thermo Fisher Scientific) following the
319
manufacturer’s instructions.
320

Page 13

13


321
Oligonucleotide immunoprecipitation
322

323
The Raji cell lysate (1 mg protein in 1 mL) was incubated with 40 nM AS1411-
324
cotinine/20 nM anti-cotinine antibody complexes, 40 nM CRO26-cotinine/20 nM anti-
325
cotinine antibody complexes, or 40 nM AS1411-cotinine/20 nM control antibody
326
complexes at 4°C overnight on an end-over-end rotator. Protein A-sepharose beads
327
(40 μL, Repligen) were added to the lysate mixture and incubated with rotation for 2 h
328
at 4°C. After centrifugation at 800 g for 1 min, the immunoprecipitates were washed
329
three times with wash buffer (20 mM Tris-Cl, pH 7.5, 150 mM NaCl, and 1% Triton X-
330
100), resuspended in 4× SDS loading buffer, and denatured at 95°C for 10 min. All
331
samples were analyzed SDS-PAGE using 4–12% Bis-Tris gel and transferred onto a
332
nitrocellulose membrane. The membrane was blocked with 5% nonfat milk in TBST
333
and then treated with mouse anti-nucleolin IgG (1:100; Santa Cruz Biotechnology).
334
After the membrane was washed three times with TBST, it was incubated with HRP-
335
conjugated rabbit anti-mouse IgG diluted 1:5,000 in TBST at room temperature for 1 h.
336
The membrane was washed three times with TBST, and protein bands were visualized
337
by the addition of the SuperSignal Pico West chemiluminescent substrate (Thermo
338
Fisher Scientific) following the manufacturer’s instructions.
339

340
Enzyme immunoassays
341

342
The wells of microtiter plates (Corning Costar Corp., Cambridge, MA) were coated by
343
the addition of 50 ng human VEGF165 (R&D Systems, Minneapolis, MN) dissolved in 20
344
μL PBS to each well for an overnight incubation at 4°C. After washing with PBS, the
345
wells were incubated with 150 μL PBS containing 3% bovine serum albumin (BSA) for
346

Page 14

14

2 h and then washed with PBS. Subsequently, both the 100 nM pegaptanib-cotinine/50
347
nM anti-cotinine antibody complex and 100 nM bevacizumab were serially diluted 10-
348
fold in PBS containing 3% BSA and added to each well. The plates were incubated for
349
1 h at room temperature and then washed five times with 0.05% Tween 20 in PBS
350
(PBST). Subsequently, a 50-μL aliquot of HRP-conjugated rabbit anti-human IgG
351
(Thermo Fisher Scientific), diluted 1:5,000 in PBS with 3% BSA, was added to each
352
well and incubated for 1 h at room temperature. After washing four times with 0.05%
353
PBST, peroxidase activity was detected by the addition of 50 μL 3,3',5,5'-
354
tetramethylbenzidine substrate solution (Thermo Fisher Scientific) to each well. The
355
plates were incubated for 10 min at room temperature, and the absorbance at 650 nm
356
was measured using a Multiskan Ascent instrument (Labsystems, Helsinki, Finland).
357

358
Acknowledgements
359

360
This work was supported by a grant 2011-0022972 from Ministry of Education, Science
361
and Technology, Republic of Korea.
362

363
References
364

365
Backmann N, Zahnd C, Huber F, Bietsch A, Pluckthun A, Lang HP, Guntherodt HJ,
366
Hegner M and Gerber C. A label-free immunosensor array using single-chain antibody
367
fragments. Proc Natl Acad Sci U S A 2005;102:14587-92
368
Baldrich E, Acero JL, Reekmans G, Laureyn W and O'Sullivan CK. Displacement
369
enzyme linked aptamer assay. Anal Chem 2005;77:4774-84
370
Bates PJ, Kahlon JB, Thomas SD, Trent JO and Miller DM. Antiproliferative activity of
371
G-rich oligonucleotides correlates with protein binding. J Biol Chem 1999;274:26369-
372
77
373

Page 15

15

Bender DA. Optimum nutrition: thiamin, biotin and pantothenate. Proc Nutr Soc
374
1999;58:427-33
375
Blank M, Weinschenk T, Priemer M and Schluesener H. Systematic evolution of a DNA
376
aptamer binding to rat brain tumor microvessels. selective targeting of endothelial
377
regulatory protein pigpen. J Biol Chem 2001;276:16464-8
378
Borisov SM and Wolfbeis OS. Optical biosensors. Chem Rev 2008;108:423-61
379
Chen CM, Chiang SY and Yeh NH. Increased stability of nucleolin in proliferating cells
380
by inhibition of its self-cleaving activity. J Biol Chem 1991;266:7754-8
381
Chen Z, Tabakman SM, Goodwin AP, Kattah MG, Daranciang D, Wang X, Zhang G, Li
382
X, Liu Z, Utz PJ, Jiang K, Fan S and Dai H. Protein microarrays with carbon nanotubes
383
as multicolor Raman labels. Nat Biotechnol 2008;26:1285-92
384
Dapic V, Abdomerovic V, Marrington R, Peberdy J, Rodger A, Trent JO and Bates PJ.
385
Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. Nucleic
386
Acids Res 2003;31:2097-107
387
Dapic V, Bates PJ, Trent JO, Rodger A, Thomas SD and Miller DM. Antiproliferative
388
activity of G-quartet-forming oligonucleotides with backbone and sugar modifications.
389
Biochemistry 2002;41:3676-85
390
Ellington AD and Szostak JW. In vitro selection of RNA molecules that bind specific
391
ligands. Nature 1990;346:818-22
392
Fang SH and Yeh NH. The self-cleaving activity of nucleolin determines its molecular
393
dynamics in relation to cell proliferation. Exp Cell Res 1993;208:48-53
394
Ferreira CS, Papamichael K, Guilbault G, Schwarzacher T, Gariepy J and Missailidis S.
395
DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody
396
sandwich ELISA for the early diagnosis of epithelial tumours. Anal Bioanal Chem
397
2008;390:1039-50
398
Gao L, Zhuang J, Nie L, Zhang J, Zhang Y, Gu N, Wang T, Feng J, Yang D, Perrett S
399
and Yan X. Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. Nat
400